The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | How can precision medicine improve outcomes in GI oncology?
Dirk Arnold, MD, PhD, Asklepios Tumorzentrum Hamburg, Hamburg, Germany, reflects on the future of precision medicine in gastrointestinal (GI) cancers. Precision medicine has many benefits for patients, including lower toxicity and improved therapeutic efficacy. Additional research is needed to elucidate novel biomarkers to improve patient selection and effectively find patients who benefit will from select therapies. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
